Rigel Pharmaceuticals Inc RIGL
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Rigel to Participate in Upcoming September Investor Conferences
-
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
-
Rigel Reports Second Quarter 2026 Financial Results
-
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
-
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arvinas, Pfizer Tap Rigel Pharmaceuticals to Bring Veppanu to Market
Trading Information
- Previous Close Price
- $46.97
- Day Range
- $46.45–48.00
- 52-Week Range
- $24.95–52.24
- Bid/Ask
- $45.19 / $49.50
- Shares Outstanding
- 18.68M
- Market Cap
- $880.76M
- Volume/Avg
- 185,673 / 305,534
Key Statistics
- Price/Earnings (Normalized)
- 11.97
- Price/Sales
- 3.32
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 174
- Website
- https://www.rigel.com
Valuation
|
Metric
|
RIGL
|
|---|---|
Price/Earnings (Normalized) | 11.97 |
Price/Book Value | 2.06 |
Price/Sales | 3.32 |
Price/Cash Flow | 8.99 |
Price/Earnings
RIGL
Financial Strength
|
Metric
|
RIGL
|
|---|---|
Quick Ratio | 1.58 |
Current Ratio | 1.94 |
Interest Coverage | 15.00 |
Quick Ratio
RIGL
Profitability
|
Metric
|
RIGL
|
|---|---|
Return on Assets (Normalized) | 84.20% |
Return on Equity (Normalized) | 118.22% |
Return on Invested Capital (Normalized) | 100.18% |
Return on Assets
RIGL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?rQZRL! | LOCK|S##B | $128B | |||
| Moderna Inc
MRNA
| LOCK|@$ks?$& | LOCK|>wv | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|rx&!N& | LOCK|Ys&b | $76B | |||
| argenx SE ADR
ARGX
| LOCK|XrShT@! | LOCK|<Q | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|>?S$rnC | LOCK|hH^ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|dX#<x^ | LOCK|@#rFs | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|>@$wRLx^ | LOCK|#qCD | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|k>&z&Z& | LOCK|SYx | $24B | |||
| Incyte Corp
INCY
| LOCK|Z!Z<X& | LOCK|kH! | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|l@Fp?D | LOCK|k@$ | $15B |
United States